Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05566769 · ClinicalTrials.gov registry record · NA

Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

A NA study of Neuromyelitis Optica, sponsored by Ad scientiam.

Recruiting
Registry status
NA
Development phase
103
Enrollment target
20
Study locations

NCT05566769 is a NA study of Neuromyelitis Optica that is actively recruiting participants, run by Ad scientiam. The registered enrollment target is 103 participants, below the 499-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05566769, a NA study of Neuromyelitis Optica, is actively recruiting participants, sponsored by Ad scientiam.

RECRUITING
Registry status
NA
Development phase
103 participants
Enrollment target
20
Study locations

Study Summary

NMOSDCopilot is a digital tool developed for the self-assessment of Neuromyelitis Optica Spectrum Disorder symptoms that impact patients' functioning and quality of life. It has been co-designed with the help of patient advocacy groups, NMOSD patients and medical experts. It includes a smartphone-based application for patients, connected to a web portal developed for healthcare professionals (HCSPs). The patient application is composed of vision, walking, cognition, and dexterity e-active tests inspired by clinical standards, as well as e-questionnaires. The HCP web portal is a desktop-based software that allows HCPs to access the results generated via the patient application and facilitates remote monitoring of patients' symptoms. The objectives of this study are to validate the accuracy, reliability and reproducibility of the unsupervised at-home self-assessment of symptoms on the patient's smartphone versus the standard in-clinic testing, as well as to evaluate the safety of use of the tool, its usability, and satisfaction towards the patient application among NMOSD patients, and the HCP web dashboard among HCPs.

Conditions Studied

Neuromyelitis Optica

Interventions

  • DEVICE NMOSDCopilot smartphone application

Study Locations (20)

Other

  • Hôpital Roger Salengro - Lille
  • CHU Marseille - La Timone - Marseille
  • CHU de Montpellier - Montpellier
  • Hopital Pasteur 2 - Nice
  • Hopital La Pitié Salpétrière - Paris
  • CHU Rouen - Rouen
  • Hopital de Hautepierre - Strasbourg
  • CHU Toulouse - Hôpital Purpan - Toulouse
  • Universitätsklinikum Carl Gustav Carus - Dresden
  • Universitätsklinik Essen - Essen

California

  • University of Southern California - Los Angeles
  • University of California Davis Health - Sacramento

Florida

  • University of south Florida - Tampa

Illinois

  • NorthShore University HealthSystem - Evanston

Maryland

  • Johns Hopkins Outpatient Center (now called Levi Watkins, Jr., M.D., Outpatient Center) - Baltimore

Massachusetts

  • Massachussets General Hospital - Boston

Missouri

  • Washington University in St. Louis - Washington

Nevada

  • CC Lou Ruvo Center for Brain Health - Las Vegas

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2023-11-03
Est. Completion 2026-09
Phase NA

Sponsor

Ad scientiam

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05566769

The ClinicalTrials.gov registry entry for NCT05566769 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (79% lower). The listed sponsor is Ad scientiam, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neuromyelitis Optica appearing as the primary indexed condition, and to 1 intervention - of which NMOSDCopilot smartphone application is the first listed.

NCT05566769 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT05566769 about?

NCT05566769 is a clinical study titled "Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD". NMOSDCopilot is a digital tool developed for the self-assessment of Neuromyelitis Optica Spectrum Disorder symptoms that impact patients' functioning and quality of life. It has been co-designed with the help of patient advocacy groups, NMOSD patients and medical experts. It includes a smartphone-ba...

What is the current status of trial NCT05566769?

This trial is currently recruiting. It is a NA study. The enrollment target is 103 participants. The study started on 2023-11-03. Estimated completion is 2026-09.

What conditions does trial NCT05566769 study?

This clinical trial studies the following conditions: Neuromyelitis Optica.

What interventions are being tested in trial NCT05566769?

The interventions under investigation include: NMOSDCopilot smartphone application (DEVICE).

Who is sponsoring clinical trial NCT05566769?

This trial is sponsored by Ad scientiam, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05566769 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuromyelitis Optica

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neuromyelitis Optica

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.